News

Li and Shao discussed the heavy disease burden of type 2 diabetes in the VA population and outlined the VA MOVE! study.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 notable dermatology updates from the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference.

At SLEEP 2025, Sachdeva discussed the evolving legal implications of AI use in sleep medicine, including clinician liability, informed consent, and responsible integration into care.

Discover how the CATALYST trial reveals mifepristone's potential to enhance glycemic control and weight loss in challenging type 2 diabetes cases.

Mifepristone shows promise in improving glycemic control and reducing weight in patients with hypercortisolism and type 2 diabetes.

The Phase 3 HYPERION trial achieved its primary endpoint of lower time to clinical worsening, measured by a variety of related factors.

Maridebart cafraglutide shows potential as a monthly treatment for obesity and type 2 diabetes, demonstrating significant weight loss and glycemic improvements.

Parent company Novo Nordisk has announced intentions to submit the treatment for approval later in 2025.

At SLEEP 2025, HCPLive spoke with Narcisse about NHANES-based findings suggesting longer sleep duration is associated with richer and more diverse oral microbiomes.

A single 25 mg dose of synthetic psilocybin led to a significant reduction in depression severity at 6 weeks in the pivotal COMP005 trial for TRD, meeting its primary endpoint.

Data from the Phase 1/2 BEACON trial indicate the efficacy and safety of this investigative 1-time therapy, particularly in decreasing blood cell sickling.

This analysis highlights the risk of superficial fungal infections among patients with moderate-to-severe psoriasis given biologics such as IL-17 inhibitors.

Sandforth emphasized the important of achieving prediabetes remission for preventing T2D as seen in his new research.

Explore groundbreaking findings from the REDEFINE trials on CagriSema's impact on weight loss and diabetes management at ADA 2025.

Philis-Tsimikas shared the latest findings demonstrating inferiority after switching from daily basal insulin to weekly insulin efsitora.

Kevin Sayer joins the program to discuss the latest from Dexcom and preview where the business is headed in an evolving diabetes landscape.

A new study reveals once-weekly efsitora alfa effectively lowers blood glucose in type 2 diabetes.

Steger discussed findings from a 6-month lifestyle investigating TRE+ER and IER.

A global study reveals that universal access to semaglutide could save 28 million lives and significantly reduce obesity and diabetes worldwide.

CagriSema shows weight loss results in recent trials comparable to existing interventions.

Xue discussed her research developing a personalized prediction algorithm for predicting responders to a DPP-style intervention.

A phase 3 trial reveals ecnoglutide significantly reduces body weight in overweight patients, showcasing its potential as a novel obesity treatment.

New findings reveal semaglutide significantly enhances walking ability and quality of life for patients with T2D and PAD.

A new study reveals hybrid closed-loop technology significantly improves glucose control for pregnant women with T1D.

Automated insulin delivery systems enhance blood glucose control for pregnant women with type 1 diabetes, potentially advancing diabetes care.

Semaglutide 7.2 mg shows promising results, achieving a mean 21% weight loss in obesity treatment.

The ACHIEVE-1 trial reveals orforglipron's potential as a breakthrough treatment for type 2 diabetes.

New research reveals amycretin's promising potential for weight loss in obesity treatment, advancing to phase 3 trials for effective management options.